Immunochemistry MarketAs per the latest report on the in-vitro diagnostics device market from iData Research, increasing immunoassay test volumes is the major factor that drives growth in the immunochemistry market. The growth may be the result of high incidence of cardiovascular disorders and cancers among aging baby boomers coupled with unhealthy lifestyle choices. The report that pertains to a forecast period of 10 years (2012 – 2022) for the United States finds that established manufacturers – Siemens Healthcare and Roche Diagnostics lead the US immunochemistry market.

The leading competitor in the market, Siemens Healthcare Diagnostics comes with nearly a 30% market share. This manufacturer has gained a prominent position through their Dimension® line of analyzers, which can be customized to streamline workflow. The company also offers a line of reagents for use in their analyzers and systems. One of the largest clinical diagnostics companies in the world, Siemens enjoys significant brand recognition, which helps encourage sales in the immunochemistry market, as labs can be fully furnished with Siemens products.

The second leading competitor in the market, Roche Diagnostics has almost 20% market share. Roche’s Cobas product line includes standalone immunoassay and clinical chemistry analyzers, as well as modular systems for immunochemistry. Other competitors mentioned in the market report are Beckman Coulter, Abbott Diagnostics, Ortho, Clinical Diagnostics, and Sysmex America among others.

An immunoassay test relies on biochemistry to measure the presence and/or concentration of an analyte. With increasing health awareness among people, strong emphasis by regulatory organizations on preventative care to contain costs, and continuous technological advancements, immunochemistry testing has become an integral part of modern health care practices as well as clinical laboratories. Even the current point-of-care QuikScreen drug test cup is based on a visually read competitive binding immunoassay method for screening without the need of instrumentation.

Based on iData Research report, the market includes integrated, immunoassay, microscopy urinalysis and clinical chemistry analyzers, as well as reagents for immunoassay and clinical chemistry testing. One of the factors driving the increased sales of these analyzers is that almost every hospital in the United States has a core lab that has one or more of these analyzers. Moreover, large hospitals usually have a primary analyzer along with a backup unit. Manufacturers usually enter into reagent rental contracts with large hospitals or reference labs to sell these systems.

With reagent rental program, the cost of the analyzer is recovered through the sales of reagents. When the contract ends, the device is either returned to the manufacturer or the contract is extended again. Sometimes, the analyzer is sold to the customer at a lower price.